Weight reduction course boosts impact of GLP-1 agonist

Introduction Studies describing the weight reducing effect of GLP-1 agonists include placebo controlled trials. Such trials might imbed an independent weight reduction course (WredCourse: calory reduction, physical activity and counseling) in parallel to the tested substance. However, in real world it is not unusual that this medication is beeing taken without concomittant WredCourse. We were interested which weight reduction under these conditions is acchieved and if the additional WredCourse appears to be necessary.

Method We looked for an answer in data sets deriving from the literature and from our own patient treatment records. We compared group results in controls with standard care but patients refusing WredCourse (group Control, Gr 1), groups treated with a WredCourse without an GLP-1 Agonist (group only WredCourse, Gr 2), groups treated with GLP-1 Agonist only without a WredCourse (group only Med, Gr 3) and groups with both procedures (group both procedures, Gr 4). Data from Gr 1 , Gr 2 and Gr 3 derived from our institution, Data from Gr 2 and Gr 3 and Gr 4 could be found in the literatur. The evaluated data refer to a treatment with Semaglutid 1 mg/week.

Results (weigt reduction% (mean) at the end of 1 year):

Gr 1 (Control)... our institution:.................2,3% *;........published data on Semaglutid: none...................

Gr 2 (only Wred Course) our institution....8.6%(3);.....published data on Semaglutid: 3- 5% (4,5,6,7,8 )

...........................(independent of GLP-1 studies)........(controls in GLP-1 studies)..................................

Gr 3 (only med) our institution:................ 5,6% *.......published data on Semaglutid: 6.6 , 6,0% (1,2),

Gr 4 (both):.......our institution:..none .........................published data on Semaglutid: 8,6% (4)............

*Patients in Gr 1 and Gr 3 from our institution were randomly selected to give a sample similar to Gr 2 (3), (n=18)

Conclusion: When comparing studies with semaglutid on the weight reduction, there is a discrepancy in published data between the effect of the drug when a WredCourse is offered concomittant with the medikation or not. When the drug is taken without a WredCourse its effect seams to be lower than it can be expected from the studies with it. These data show that given in the in Germany permitted dosis to treat diabetes (1mg/week) Semaglutid alone will achieve a weight reduction only less than the effect of appropriate WredCourses available without the drug. This means that in order to achieve the full effect of the medication a concurrent WredCourse in general seams to be necessary. [1] [2] [3] [4] [5] [6] [7] [8]

Interessenkonflikt

Anna von Lilienfeld-Toal gibt keine Interessenskonflikte an. Dietrich Tews war in Beratungsgremien, erhielt Vortragshonorare und führte Studien durch bei folgenden Firmen und Organisationen: Sanofi, Abbott, AstraZeneca, Santis, Ascensia, BerlinChemie, OmniaMed, Wort & Bild Verlag, Elli Lilly, Böhringer-Ingelheim, NovoNordisk, MSD, Hessische Genossenschaft Diabetologen eG, winDiab, Dexcom, Roche. Hermann von Lilienfeld-Toal erhielt Vortagshonorare und Einladungen zu Kongressen von Novo, Sanofi, Berlin Chemie, Böhringer Ingelheim, Lilly, Novartis , Hessische Genossenschaft Diabetologen eG.. Er hat Anteile und Patente in folgenden Unternehmungen: – Elté Sensoric GmbH ( non-invasive glucose measuring), Quantune Technologies GmbH (QCL Herstellung ), Koala GbR: kontinuierliche Manschetten-lose Blutdruckmessung. Er hat ein Buch veröffentlicht: „Jetzt nehmen Sie doch mal ein bisschen ab!- Ja, wie denn, Herr Doktor?!“

• References

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8

Publication History

Article published online:
18 April 2024